The Associations Between CYP2D6 Metabolizer Status and Pharmacokinetics and Clinical Outcomes of Venlafaxine: A Systematic Review and Meta-Analysis

Abstract

Background The association between CYP2D6 metabolizer status and clinical outcomes of venlafaxine was extensively investigated previously, but no widely accepted conclusion has been reached so far. To obtain a more precise estimation of the association, a systematic review by meta-analysis was conducted in the present study.

Methods The PubMed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastructure, Technology of Chongqing, and Wan Fang Database were searched for eligible studies up to August 2018.

Results Fourteen related studies involving 1035 patients were finally included. Significant associations were found among 3 CYP2D6 phenotypes (NM, IM, and PM) and most pharmacokinetic parameters of venlafaxine. However, CYP2D6 phenotypes were not associated with Hamilton Depression Rating Scale response of venlafaxine. In addition, we also found no significant association between CYP2D6 phenotype and overall rate of adverse events.

Conclusions CYP2D6 metabolizer status had significant influence on venlafaxine pharmacokinetics, but insufficient evidence demonstrated that CYP2D6 metabolizer status was associated with its therapeutic effects and overall rate of adverse events, which provided further evidence regarding the relationship between CYP2D6 metabolizer status and venlafaxine.

Key words

CYP2D6 - meta-analysis - phenotype - venlafaxine - polymorphism

^* These authors contributed equally to this work.

• References

• 1 Holliday SM, Benfield P. Venlafaxine. Drugs 1995; 49: 280-294
• 2 Cipriani A, Furukawa TA, Salanti G. et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. Lancet 2009; 373: 746-758
• 3 de Silva VA, Hanwella R. Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: A meta-analysis of published studies. Int Clin Psychopharmacol 2012; 27: 8-16
• 4 Veefind AH, Haffmans PM, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 2000; 22: 202-208
• 5 Dean L. Venlafaxine therapy and CYP2D6 genotype. In: Pratt V. (ed.) Source Medical Genetics Summaries. Bethesda: National Center for Biotechnology Information; 2012. –2015
• 6 Otton SV, Ball SE, Cheung SW. et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996; 41: 149-156
• 7 Lindh JD, Annas A, Meurling L. et al. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. Eur J Clin Pharmacol 2003; 59: 401-406
• 8 Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 23-37
• 9 Waade RB, Hermann M, Moe HL. et al. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. Eur J Clin Pharmacol 2014; 70: 933-940
• 10 Lessard E, Yessine MA, Hamelin BA. et al. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J Clin Psychopharmacol 2001; 21: 175-184
• 11 Lobello KW, Preskorn SH, Guico-Pabia CJ. et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: A secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry 2010; 71: 1482-1487
• 12 Ng C, Sarris J, Singh A. et al. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Hum. Psychopharmacol Clin Exp 2013; 28: 516-522
• 13 Brandl EJ, Tiwari AK, Zhou X. et al. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics J 2014; 14: 176-181
• 14 Shams ME, Arneth B, Hiemke C. et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006; 31: 493-502
• 15 Moher D, Liberati A, Tetzlaff J. et al. Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. Int J Surg 2010; 5: 336-341
• 16 Little J, Higgins JP, Ioannidis JPA. et al. Strengthening the reporting of genetic association studies (STREGA) – An extension of the STROBE statement. PLoS Med 2009; 6: e22
• 17 Li X, Yu C, Wang T. et al. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: A systematic review and meta-analysis. Eur J Clin Pharmacol 2016; 72: 1185-1193
• 18 Tang H, Yan Y, Wang T. et al. Effect of follicle-stimulating hormone receptor Asn680Ser polymorphism on the outcomes of controlled ovarian hyperstimulation: An updated meta-analysis of 16 cohort studies. J Assist Reprod Genet 2015; 32: 1801-1810
• 19 Swen JJ, Nijenhuis M, de Boer A. et al. Pharmacogenetics: From bench to byte–an update of guidelines. Clin Pharmacol Ther 2011; 89: 662-673
• 20 Nichols AI, Lobello K, Guico-Pabia CJ. et al. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status. J Clin Psychopharmacol 2009; 29: 383-386
• 21 Sterne JAC, Egger M, Moher D. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S. (eds.) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Available at http://handbook-5-1.cochrane.org/
• 22 Fukuda T, Yamamoto I, Nishida Y. et al. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol 1998; 47: 450-453
• 23 Fukuda T, Nishida Y, Zhou Q. et al. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol 2000; 56: 175-180
• 24 Jiang F, Kim HD, Na HS. et al. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: Exploring predictive biomarkers for treatment outcomes. Psychopharmacology 2015; 232: 1899-1909
• 25 Nichols AI, Focht K, Jiang Q. et al. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D extensive and poor metabolizers: A randomized, open-label, two-period, parallel-group, crossover study. Clin Drug Investig 2011; 31: 155-167
• 26 Preskorn S, Patroneva A, Silman H. et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 2009; 29: 39-43
• 27 Van Nieuwerburgh FC, Denys DA, Westenberg HG. et al. Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6. Int J Psychiatry Clin Pract 2009; 13: 345-348
• 28 Taranu A, Colle R, Gressier F. et al. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?. Pharmacogenomics 2017; 18: 639-650
• 29 Whyte EM, Romkes M, Mulsant BH. et al. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. Int J Geriatr Psychiatry 2006; 21: 542-549
• 30 Sterne JAC, Egger M, Moher D, Addressing reporting biases. In: Higgins JPT, Green S. (eds.) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Available at http://handbook-5-1.cochrane.org/
• 31 Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance. Clinical Pharmacokinetics 2009; 48: 761-804
• 32 Hicks JK, Sangkuhl K, Swen JJ. et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 2016; 102: 37-44
• 33 Berm E, Kok R, Hak E. et al. Relation between CYP2D6 genotype, phenotype and therapeutic drug concentrations among nortriptyline and venlafaxine users in old age psychiatry. Pharmacopsychiatry 2016; 49: 186-190
• 34 Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999; 19: 467-489
• 35 Castanares-Zapatero D, Gillard N, Capron A. et al. Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism. Forensic Sci Int 2016; 266: e48-e51
• 36 Lessard E, Yessine MA, Hamelin BA. et al. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999; 9: 435-443
• 37 Lingjaerde O, Ahlfors UG, Bech P. et al. The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1-100